SUMMARY The long-term prognostic implications of the electrocardiographic location of a myocardial infarction and the subsequent retention or disappearance of diagnostic Q waves were examined in patients enrolled in the Aspirin Myocardial Infarction Study (AMIS). The 4524 participants, ages 30-69 years, had sustained a myocardial infarction 8 weeks to 60 months before randomization to aspirin and placebo groups. Subjects were followed for at least 3 years (average 38.2 months). Using the Minnesota Code, myocardial infarctions were classified according to three electrocardiographic locations: lateral, inferior and anterior, with further subdivision into major, moderate and minor criteria based on Q-wave duration and Q/R ratios. Total mortality was not significantly different among patients with single infarct sites: lateral 11.8%, inferior 8.0% and anterior 9.4%. Patients with multiple electrocardiographic infarct locations had a significantly higher mortality (14.6%, p < 0.0002). Participants with Minnesota Code major criteria of infarction also had a significantly higher mortality (10.6%) than those with moderate (7.2%) or minor (7.4%) criteria (p < 0.01).
THE ABSENCE or disappearance of diagnostic Q waves after a myocardial infarction (MI) and the electrocardiographic location of the infarction reportedly have long-term prognostic implications. [1] [2] [3] The Coronary Drug Project data suggest an improved prognosis for patients with a previous inferior wall MI as well as for patients with no diagnostic Q waves on the ECG.' To test these hypotheses, we examined the records of all patients in the Aspirin Myocardial Infarction Study (AMIS) who were followed for at least 3 years.
Material and Methods AMIS was designed to investigate whether aspirin therapy would reduce mortality over a 3-year period among patients who had survived a documented MI. Sample size, dosage and eligibility criteria have been published. 4 The participants were 30-69 years old, were in New York Heart Association class I or II and had sustained an MI 8 weeks to 60 months before randomization. MIs were documented by specific criteria, including diagnostic ECG changes, elevated serum en-zymes and typical symptoms.4 Of 4524 patients in the study, 2257 were in the placebo group and 2267 were in the aspirin group. Each patient was followed for at least 3 years (average 38.2 months). Total mortality was 10.8% in the aspirin group and 9.7% in the placebo group; noncardiovascular mortality was 1.4% and 0.9%, respectively. These differences were not statistically significant.5 Because aspirin had no significant effect on mortality, we pooled the data from both groups.
Because participants who entered the trial more than 1 No 7, JUNE 1982 mined by duration and depth of Q waves and the leads in which they appeared. 6' 7 Contingency- Six hundred two patients had diagnostic Q waves (major, moderate or minor criteria) on the qualifying ECG, but not on the baseline ECG. Table 2 shows the interval from the acute MI to the baseline ECG that The CDP data therefore conflicted with data from previous studies. In the CDP study, the 2035 men in the placebo group were followed for at least 3 years.1 Although the exact number of patients who lost significant Q waves during their follow-up period is not mentioned, 748 patients (36.8%) had no diagnostic Q waves at entry into the study. Because the resting ECG was coded using the Minnesota Code, Q waves could be classified as major, moderate or minor. Infarct survivors with major Q patterns on the baseline resting ECG had over twice the mortality of those with no residual recordable Q waves after infarction (18.4% vs 8.4%, p < 0.01). The presence of moderate and minor Q waves was also significantly related to mortality compared with the absence of Q waves. The CDP study led to the generally held impression that absence or disappearance of a diagnostic Q wave after MI carries favorable prognostic implications.
The present report agrees with earlier publications concerning patients in whom significant Q waves were lost. In the AMIS cohort, the mortality associated with the absence or loss of Q waves did not differ from that in patients who had a single infarct location and persistent Q waves. Those with extensive areas of infarction, however, as indicated by multiple infarct sites or major coding criteria, had a significantly higher total mortality than patients who lost Q waves.
One reason for the discrepancy between the CDP study and other studies may be that earlier studies specifically referred to loss of Q waves, while the CDP study referred only to the fact that there was no Q wave present at baseline. This difference may be secondary to major differences in the population studied, because a large portion of the CDP patients had nontransmural infarction and no Q waves at the time of qualification.
Only 18.9% of the AMIS population (compared with 36.8% in the CDP study) had no Q wave at entry into the study and only 14.2% actually lost Q waves that were present on the qualifying ECG. Q loss occurred most frequently in patients with moderate (35.6%) or minor (39.7%) coding criteria and least commonly in those with major (16.1%) or multiple (8.6%) criteria.
Location of Infarction
The prognostic implications of the locations of the MI by Q-wave distribution are controversial. Among men in the CDP study who survived 3 months after MI, those with inferior MI had a significantly lower mortality than those with anterior or lateral infarctions.1 The Framingham Study2 and Kennedy et al.3 also found poorer long-term survival for patients with anterior infarctions than for those with inferior infarctions.
Geltman and co-workers12 also found a significantly lower mortality (mean follow-up 21.7 months) in their inferior infarction subgroup. They postulate that this difference depended on the larger infarct size of the anterior subgroup as estimated by serum enzymes.
Weinberg13 reported no significant difference in 6-year mortality in patients with anterior (29 of 77, 38%) VOL 65, No 7, JUNE 1982 and those with inferior MI (24 of 74, 32%), although there was a significantly higher immediate mortality in the anterior subgroup. These findings of higher immediate mortality with comparable long-term survival are similar to other reported results.'1419 The AMIS data show that among patients who lived at least 2 months after MI, mortality did not differ for the three locations. However, the magnitude of infarctions is a significant predictor of mortality, as reflected in the worsened prognosis in patients with multiple infarct sites and those with major Q-wave criteria.
Limitations of the Study Our data only apply to patients who are stable (New York Heart Association functional class I or II) and have survived at least 2 months after their acute event.
Horan et al. 20 reported that significant Q waves or Q waves greater than 30 msec in a single electrocardiographic zone alone may be unreliable predictors of necrosis, with a sensitivity in one autopsy study of only 61 % and a specificity of 89%. 20 The accuracy of predicting infarction increased significantly when Q waves were found in both anterior and inferior leads. However, the AMIS investigators emphasized Q waves knowing that the patients had met multiple criteria for MI, including serial ECG changes, enzyme elevation and symptoms.
Localization of the infarct using Q waves was also shown to be unreliable by the study of Horan et al.,20 in which anatomic infarct sites frequently overlapped. This is consistent with our findings of no mortality difference in single site infarct groups; however, these groups (lateral, inferior and anterior) refer to ECG rather than anatomic localization.
Finally, the difference in our results from those of the CDP may reflect more than differences in populations. The 3-year mortality in the CDP placebo subgroup was 12.6%,' compared with the 3-year mortality of 9.6% in the AMIS aspirin group and 8.8% in the placebo group.' The lower mortality rate in similar, stable MI patients is significant. The reason for the lowered mortality is multifactorial and beyond the scope of this analysis, but may account for at least some of the difference in the results of our analysis and those of the CDP.
